Back to search

National and Kapodistrian University of Athens

Μοριακή μελέτη παραγόντων που σχετίζονται με θρόμβωση και συσχέτισή τους με κληρονομική προδιάθεση για καρκίνο του στόματος

Abstract

dc:description

Introduction Carcinogenesis is a genetic disease at the cellular level. It is a case of irreversible loss of gene regulation, which controls growth and differentiation. This event is due to changes in DNA and the cancer cells show uncontrolled mitotic activity, which makes these cells to look more like immature cells rather than normal mature differentiated cell types, since they produce proteins found in embryonic cells. In every normal cell there is a normal level for protein production. Disruption of gene regulation and expression because of mutations or DNA polymorphisms may change the normal protein level. Like other types of cancer, oral squamous cell carcinoma (OSCC) is related to the coagulation system. Thromboembolism is one of the most frequent causes of death in patients with cancer. It is therefore clear that such complications occur as the cancer cells have participated in almost all factors of the haemostatic system. Given the above, in this dissertation mutations or polymorphisms were studied in genes whose protein products are associated with a) blood clotting (methyletetrahydrofolare reductase, factor V, prothrombin, factor XII, factor XIII, protein Z), b) the fibrinolysis system (plasminogen activator inhibitor-1, thrombin activated fibrinolysis inhibitor) and c) the renin-angiotensin system (angiotensin converting enzyme, angiotensinogen). Materials and Methods The C677T mutation in Methyletetrahydrofolate reductase gene (MTHFR), the Leiden mutation in the gene of factor V (FV), the G20210A mutation in the Prothrombin gene (PT), the C46T polymorphism in the gene of Factor XII (FXII), the V34L polymorphism in the gene of Factor XIII (FXIII), the polymorphism -13A/G in the Protein Z gene (PZ), the 4G/5G insertion/deletion polymorphism in the Plasminogen Activator Inhibitor-1 gene (PAI-1), the polymorphism 1040 C/T in the Thrombin Activatable Fibrinolysis Inhibitor gene (TAFI), the insertion/deletion polymorphism in Angiotensin-Converting Enzyme gene (ACE) and the M235T polymorphism in Angiotensinogen gene (AGT) were studied in 163 DNA samples from patients with oral squamous cell carcinoma and 168 samples from healthy controls with corresponding age and gender. Results For the C677T polymorphism in MTHFR gene the data of the present study revealed a statistically significant increase of T allele heterozygotes in the patients group (P= 0,043). This result seems to arise only in the subgroup of patients with a history of thrombophilia where the heterozygotes for the T allele was also significantly increased (P = 0,034). The overall data obtained for the Leiden mutation in the FV gene and the G20210A mutation in the PT gene revealed no statistically significant differences in the comparisons made between the control group and the patient’s group and subgroups. The overall data obtained for the C46T polymorphism of the FXII gene revealed a statistically significant reduction in homozygous patients P=0,008. Similarly statistically significant reductions of heterozygotes occurred in subgroups of patients with advanced stage of cancer, family history of thrombophilia and without tobacco abuse, always in relation to the control group. In the group of healthy controls (N = 135), the V34L mutation in the gene of FXIII was found in 6 homozygotes (4.44%) and 48 heterozygotes (35.56%), while in the group of patients (N = 130) there were 12 homozygotes (9.23%) and 62 heterozygotes (47.69%). This data reveals an incriminatory role for the L allele in the development of OSCC. The same pattern appears in the subgroups of patients with early cancer stage, without family history of cancer, without family history of thrombophilia, without tobacco abuse and without alcohol abuse. For the polymorphism-13A / G in the PZ gene, no statistically significant differences were shown between the group of healthy controls and the group of patients. The same picture appeared in the comparisons made between healthy controls and the various subgroups of patients. For the 4G/5G insertion/deletion polymorphism of the PAI-1 gene the overall data revealed statistically significant increase of homozygotes and heterozygotes in the patient group (P=0,001 and P=0,009 respectively) compared to the control group. This appearance of 4G allele as an incriminatory factor is confirmed by various subgroups of patients. Specifically, by the subgroup of patients with early stage of cancer, the subgroup of patients without family history of cancer, the subgroup of patients without family history of thrombophilia, the subgroup of patients with tobacco abuse and the subgroup of patients without alcohol abuse. For the polymorphism 1040C/T in the TAFI gene, in the group of healthy controls (N = 138), the mutant T allele was found in 18 homozygotes (13.04%) and 66 heterozygous (47.83%), while in patients group (N = 150) the homozygotes were 8 (5.33%) and the heterozygotes 70 (46.67%). These figures reveal a significant reduction in homozygotes (P = 0,018), while the values of OR=0,29 (less than one) and 95% CI (0,11-0,74) assign to this particular allele a protective role against the development of OSCC. This protective role of the T allele was reflected in the comparisons that took place between healthy controls and the homozygotes in the subgroups of patients with advanced cancer stage, with tobacco abuse, without tobacco abuse and without alcohol abuse. For the insertion/deletion polymorphism in the ACE gene this study revealed a statistically significant increase of homozygotes in the patients group compared with the control group. This increase of homozygotes is also reflected in the comparisons occurred between healthy controls and homozygotes in the subgroups of patients with early stage of cancer, with advanced stage of cancer, without family history of cancer, without family history of thrombophilia, without tobacco abuse and without alcohol abuse. For the M235T polymorphism of AGT gene the overall data of this study showed that the prevalence of 'mutant' high expression T allele was not significantly different in the total patient’s group and almost in any of the subgroups, compared to healthy controls. Only in the subgroup of patients with a family history of cancer the homozygotes and the heterozygotes are significantly higher than in the control group. The findings of the multivariate logistic regression for the overall cancer stages of OSCC of model A (mutant homozygotes) highlight as important independent factors in tumor development: a) age, b) gender, c) the genotype I/I of the I/D polymorphism in the ACE gene and d) the 4G/4G genotype of the 4G/5G polymorphism in the PAI-1 gene, while the same model for the early and late stages of OSCC includes only the first three factors. Model B (mutant heterozygotes) for the overall stages of OSCC highlights as important independent factors in tumor development: a) age, b) sex and c) the 4G/5G genotype of the -675 4G/5G polymorphism in the PAI-1 gene. The same model for the early stages of OSCC includes a) age, b) sex and also c) heterozygotes for the C677T polymorphism in the MTHFR gene. Finally, in the late stages of OSCC Model B includes the factors a) age, b) sex and also c) heterozygotes of the C46T polymorphism in the FXII gene, and d) heterozygotes of the V34L polymorphism in the FXIII gene. Model C (inheritance mode of mutations) shows as significant independent determinants of growth of tumor in the mouth: a) age, b) sex and c) the genotype I/I of the I/D polymorphism in the ACE gene. Conclusions Of the total 10 polymorphisms or mutations investigated in this study 3 did not show any correlation with the development of OSCC, 2 shows moderate correlation, 2 have a protective effect and 3 are closely related with the development of OSCC. Leiden mutation in the gene of factor V (FV), G20210A mutation in prothrombin gene (PT) and the -13A/G polymorphism in the gene of protein Z (PZ) does not affect oral oncogenesis. The C677T polymorphism in the gene of methyletetrahydrofolate reductase (MTHFR) and the M235T polymorphism in the angiotensinogen (AGT) gene demonstrated mild incriminatory role in the oral cavity oncogenesis. The mutant alleles of the C46T polymorphism in the gene of Factor XII (FXII) and the 1040C/T polymorphism in the thrombin activatable fibrinolysis inhibitor (TAFI) have a protective effect in terms of OSCC development. The V34L polymorphism in the gene of factor XIII (FXIII), the 4G/5G polymorphism in the plasminogen activator inhibitor -1 gene (PAI-1) and the insertion/deletion polymorphism in the angiotensin-converting enzyme (ACE) gene are closely related with the development of OSCC. Model A (mutant homozygotes) for the overall stages of OSCC highlights as important independent factors in tumor development: a) age, b) gender, c) the genotype I/I of the I/D polymorphism of ACE gene and d) genotype 4G/4G of the 4G/5G polymorphism in the PAI-1 gene, while the same model for the early and late stages of OSCC includes only the first three factors. Model B (mutant heterozygotes) for the overall stages of OSCC highlights as important independent factors in tumor development: a) age, b) sex and c) the 4G/5G genotype of the -675 4G/5G polymorphism in the PAI-1 gene. The same model for the early stages of OSCC includes a) age, b) sex and also c) heterozygotes for the C677T polymorphism in the MTHFR gene. Finally, in the late stages of OSCC Model B includes the factors a) age, b) sex and also c) heterozygotes for the polymorphism C46T in the FXII gene, and d) heterozygotes for the polymorphism V34L in the FXIII gene. Model C (inheritance mode of mutations) reveals a) age, b) sex and c) the genotype I/I of the I/D polymorphism in the ACE gene as significant independent determinants of tumour growth in the mouth. The possibility of molecular detection of ACE polymorphism associated with increased risk for AKS may contribute to AKS prevention in the general population.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2011

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Βυλλιώτης, Αντώνιος
  • Vylliotis, Antonios

Subjects

dc:subject × 16

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/27320

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Βυλλιώτης, Αντώνιος; Vylliotis, Antonios. Μοριακή μελέτη παραγόντων που σχετίζονται με θρόμβωση και συσχέτισή τους με κληρονομική προδιάθεση για καρκίνο του στόματος. National and Kapodistrian University of Athens, 2011. http://hdl.handle.net/10442/hedi/27320